As much as we know about the genomic landscape and antitumor immune response in advanced-stage NSCLC, little has been published on the prevalence and nature of EGFR mutations and other driver alterations and PD-L1 expression in early-stage NSCLC [22,35,36,37,38,39,40]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.